The inhibition of TGF-βR to target components of the tumor microenvironment warrants consideration as a potential therapy for pancreatic cancer, particularly in patients who have already lost tumor-suppressive TGF-β signals in the epithelium [6]. The gene discussed is TGFB1; the disease is neoplasm.